Evidence map›Paper›PMID 39261590›Full record

ArticleNature biotechnology2025

Organoid culture promotes dedifferentiation of mouse myoblasts into stem cells capable of complete muscle regeneration.

Feodor D Price, Mark N Matyas, Andrew R Gehrke, William Chen, Erica A Wolin, Kristina M Holton, Rebecca M Gibbs, Alice Lee, Pooja S Singu, Jeffrey S Sakakeeny and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Stem/progenitor cell-based therapy for Duchenne muscular dystrophy.Frontiers in cell and developmental biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Feodor D PriceDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA. feodor_price@harvard.edu.ORCID http://orcid.org/0000-0001-6773-5675
Mark N MatyasDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.
Andrew R GehrkeDepartment of Organismic and Evolutionary Biology, Harvard University, Cambridge, MA, USA.
William ChenDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-6374-8807
Erica A WolinDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.
Kristina M HoltonDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.
Rebecca M GibbsDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.
Alice LeeDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.
Pooja S SinguDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.ORCID http://orcid.org/0009-0001-8835-4123
Jeffrey S SakakeenyDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.
James M PoterackiDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-8144-0662
Kelsey GouneDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-5075-7915
Isabella T PfeifferDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.ORCID http://orcid.org/0009-0005-2512-8400
Sarah A BoswellDepartment of Systems Biology and Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-3118-3378
Peter K SorgerDepartment of Systems Biology and Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-3364-1838
Mansi SrivastavaDepartment of Organismic and Evolutionary Biology, Harvard University, Cambridge, MA, USA.
Kathleen Lindahl PfaffDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.
Emanuela GussoniDivision of Genetics and Genomics and the Stem Cell Program, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9915-3677
Sean M BuchananDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.
Lee L RubinDepartment of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA. lee_rubin@harvard.edu.ORCID http://orcid.org/0000-0002-8658-841X

Funding

Pharmaco Response Signatures and Disease MechanismU54HL127365 · NHLBI · HARVARD MEDICAL SCHOOL · PI SORGER, PETER KARL · 2014 to 2019
$13.1M
Genetic Analysis and Manipulation Core (GAEC)P50HD105351 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI Hisashi Umemori · 2021 to 2026
$9.4M
NHLBI NIH HHS U54 HL127365NICHD NIH HHS P50 HD105351
6 · The paper itself

Abstract

Experimental cell therapies for skeletal muscle conditions have shown little success, primarily because they use committed myogenic progenitors rather than true muscle stem cells, known as satellite cells. Here we present a method to generate in vitro-derived satellite cells (idSCs) from skeletal muscle tissue. When transplanted in small numbers into mouse muscle, mouse idSCs fuse into myofibers, repopulate the satellite cell niche, self-renew, support multiple rounds of muscle regeneration and improve force production on par with freshly isolated satellite cells in damaged skeletal muscle. We compared the epigenomic and transcriptional signatures between idSCs, myoblasts and satellite cells and used these signatures to identify core signaling pathways and genes that confer idSC functionality. Finally, from human muscle biopsies, we successfully generated satellite cell-like cells in vitro. After further development, idSCs may provide a scalable source of cells for the treatment of genetic muscle disorders, trauma-induced muscle damage and age-related muscle weakness.

Indexed as

Cell DedifferentiationMuscle, SkeletalMyoblastsOrganoidsRegenerationStem CellsAnimalsCell Culture TechniquesCell DifferentiationCells, CulturedHumansMiceMuscle DevelopmentSatellite Cells, Skeletal Muscle

Identifiers

PMID39261590
PMCPMC12091575

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.